Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/94005
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes
Author: Niscola, P.
Tendas, A.
Cupelli, L.
Catalano, G.
Scaramucci, L.
Giovannini, M.
Trinchieri, V.
Sharma, A.
Efficace, F.
Cartoni, C.
Piccioni, D.
Perrotti, A.
Dentamaro, T.
de Fabritiis, P.
Keefe, D.
Citation: Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012; 10(4):362-375
Publisher: Bentham Science Publishers
Issue Date: 2012
ISSN: 1871-5257
1875-6182
Statement of
Responsibility: 
Pasquale Niscola, Andrea Tendas, Luca Cupelli, Gianfranco Catalano, Laura Scaramucci, Marco Giovannini, Vito Trinchieri, Atul Sharma, Fabio Efficace, Claudio Cartoni, Daniela Piccioni, Alessio Perrotti, Teresa Dentamaro, Paolo de Fabritiis and Dorothy M.K. Keefe
Abstract: BACKGROUND: The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient's quality of life. OBJECTIVES: To review currently available measures and investigational agents to prevent OM in hematological patients. METHODS: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. RESULTS/CONCLUSIONS: Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.
Keywords: Humans
Hematologic Neoplasms
Transplantation Conditioning
Fibroblast Growth Factor 7
Mouth Mucosa
Hematopoietic Stem Cell Transplantation
Stomatitis
Rights: Copyright status unknown
DOI: 10.2174/187152512803530324
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.